Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 483,235	$ 393,772	[1]
Marketable securities	75,080	393,743	[1]
Investment in equity securities	33,662	49,148	[1]
Receivable from licensing and collaboration agreements	24,581	19,749	[1]
Prepaid expenses and other current assets	25,661	32,446	[1]
Total current assets	642,219	888,858	[1]
Property and equipment, net	15,603	30,066	[1]
Operating lease right-of-use assets	11,738	15,907	[1]
Intangible assets, net	29,310	44,934	[1]
Other assets	29,870	33,027	[1]
Total assets	728,740	1,012,792	[1]
Current liabilities:
Accounts payable	10,158	11,884	[1]
Accrued compensation and benefits	24,842	37,041	[1]
Accrued research and development liabilities	44,564	44,138	[1]
Accrued professional services	4,230	6,786	[1]
Operating lease liabilities, current portion	4,044	4,938	[1]
Deferred revenue, current portion	7,518
Other accrued liabilities	23,838	30,282	[1]
Total current liabilities	119,194	135,069	[1]
Term loan, net	422,972	430,752	[1]
Operating lease liabilities, net of current portion	13,000	17,428	[1]
Other long-term liabilities	28,226	22,069	[1]
Total liabilities	1,859,113	1,878,371	[1]
Commitments and contingencies (Note 9)
Redeemable convertible noncontrolling interests	(2,388)	1,423
Stockholders’ equity (deficit):
Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value; 500,000,000 shares authorized;155,558,848 shares issued and 149,367,087 shares outstanding as of September 30, 2022, 153,535,084 shares issued and 147,343,323 shares outstanding as of December 31, 2021	156	154	[1]
Treasury stock, at cost; 6,191,761 shares as of September 30, 2022 and December 31, 2021	(275,000)	(275,000)	[1]
Additional paid-in capital	917,333	841,530	[1]
Accumulated other comprehensive loss	(348)	(132)	[1]
Accumulated deficit	(1,780,558)	(1,436,966)	[1]
Total BridgeBio stockholders' deficit	(1,138,417)	(870,414)	[1]
Noncontrolling interests	10,432	3,412	[1]
Total stockholders' deficit	(1,127,985)	(867,002)	[1],[2]
Total liabilities, redeemable convertible noncontrolling interests and stockholders' deficit	728,740	1,012,792	[1]
2029 Notes
Current liabilities:
Notes, net	734,516	733,119	[1]
2027 Notes
Current liabilities:
Notes, net	$ 541,205	$ 539,934	[1]

[1] The condensed consolidated balance sheet as of December 31, 2021 is derived from the audited consolidated financial statements as of that date.

[2] The consolidated balances as of December 31, 2021 and 2020 are derived from the audited consolidated financial statements as of those dates.